Biograil ApS: Financial statements 2023
CVR: 40666699
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Biograil ApS (CVR 40666699) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -16,707,823 and a net result of DKK -34,799,433 compared with DKK 12,876,552 the year before. Equity in the 2023 report amounted to DKK 10,017,542. The solvency ratio was 13.1%. The company had 14 employees in the financial year.
- Gross Profit
- DKK -16,707,823
- Profit/Loss
- DKK -34,799,433
- Equity
- DKK 10,017,542
- Total Assets
- DKK 76,181,881
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -16.7 mio. | -34.8 mio. | 10 mio. | 14 |
| 2022 | - | 26.3 mio. | 12.9 mio. | 44.8 mio. | 6 |
| 2021 | - | -5.4 mio. | -7.9 mio. | 31.9 mio. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Biograil ApS has published its annual report for 2022. Gross profit came to DKK 26,317,577, and the net result was DKK 12,876,552.
About Biograil ApS
Biograil ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karsten Lindhardt. The board consists of John Michael Barberich (chair), Karsten Lindhardt, Lars Hellerung Christiansen and Robert Samuel. The company's owners include Lindhardt Holdings ApS, MTI Biograil Invest A/S and Eli Lilly and Company. The company has 23 employees (2026). In 2025, the company reported a gross profit of DKK -13,192,351 and a net result of DKK -22,366,605 compared with DKK -17,084,308 the year before. Equity in the 2025 report amounted to DKK 102,217,548.